Alaunos Therapeutics (TCRT) Debt to Equity (2016 - 2023)
Historic Debt to Equity for Alaunos Therapeutics (TCRT) over the last 4 years, with Q1 2023 value amounting to $0.37.
- Alaunos Therapeutics' Debt to Equity fell 2477.74% to $0.37 in Q1 2023 from the same period last year, while for Mar 2023 it was $0.37, marking a year-over-year decrease of 2477.74%. This contributed to the annual value of $0.43 for FY2022, which is 467.34% up from last year.
- Latest data reveals that Alaunos Therapeutics reported Debt to Equity of $0.37 as of Q1 2023, which was down 2477.74% from $0.43 recorded in Q4 2022.
- In the past 5 years, Alaunos Therapeutics' Debt to Equity registered a high of $0.71 during Q3 2022, and its lowest value of $0.35 during Q3 2021.
- In the last 3 years, Alaunos Therapeutics' Debt to Equity had a median value of $0.43 in 2022 and averaged $0.48.
- Per our database at Business Quant, Alaunos Therapeutics' Debt to Equity surged by 10031.83% in 2022 and then crashed by 2477.74% in 2023.
- Quarter analysis of 3 years shows Alaunos Therapeutics' Debt to Equity stood at $0.42 in 2021, then rose by 4.67% to $0.43 in 2022, then dropped by 14.37% to $0.37 in 2023.
- Its Debt to Equity stands at $0.37 for Q1 2023, versus $0.43 for Q4 2022 and $0.71 for Q3 2022.